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Abstract
Background—Hormonal contraception use by women may increase the risk of acquiring certain
sexually transmitted infections. We explored the effect of hormonal contraceptive use, specifically
oral contraception (OC), and depot-medroxyprogesterone acetate (DMPA) on Trichomonas
vaginalis infections in women.
Methods—We examined data from a prospective case–control study of women with
trichomoniasis and noninfected female patients recruited from 3 public sexually transmitted
disease clinics. Women with positive wet mount microscopy or T. vaginalis culture results were
classified as having trichomoniasis. Participants underwent physical examinations, sexually
transmitted infections testing and completed questionnaires which included information about
demographics, sexual behavior, douching and contraceptive use. We assessed the association
between hormonal contraceptives and trichomoniasis using bivariable and multivariable analysis
and estimated exposure odds ratios (ORs) and adjusted odds ratios (aORs) with 95% confidence
intervals (CIs).
Results—We identified 427 women with trichomoniasis and 144 uninfected women who had
information reported about contraception use. Compared with nonhormonal contraceptive use, OC
use was negatively associated with trichomoniasis in bivariable analysis (OR: 0.5; 95% CI: 0.3–
0.8). This association was no longer statistically significant after adjusting for demographic
variables, douching and condom use (aOR: 0.9; 95% CI: 0.5–1.6). Use of DMPA, compared with
nonhormonal contraceptive use, was not associated with trichomoniasis in bivariable or
multivariable analyses (OR: 1.0, 95% CI: 0.5–2.1; aOR = 1.4, 95% CI: 0.6–3.4, respectively).
Conclusions—Although OC use appeared to have a protective effect in the bivariable analysis,
the hormonal contraceptives OC and DMPA were not associated with T. vaginalis infection after
adjustment for other factors.
Copyright © 2009 American Sexually Transmitted Diseases Association All rights reserved.
Correspondence: Michelle Torok, PhD, 54A Plymouth Street, 4500, Wanganui, New Zealand. torok@email.unc.edu.
NIH Public Access
Author Manuscript
Sex Transm Dis. Author manuscript; available in PMC 2013 October 04.
Published in final edited form as:













Trichomonas vaginalis (Tv) is associated with women’s health problems that include
vaginitis, adverse pregnancy outcomes, cervical cancer and increased HIV transmission.1–5
The possible effect of hormonal contraceptive use on Tv is of particular interest because
over 100 million women worldwide use hormonal contraception such as oral contraceptives
(OC), intrauterine devices (IUD), Norplant, and depot-medroxyprogest-erone acetate
(DMPA). Sex hormones influence the reproductive immune response,6,7 and hormonal
contraceptive use affects the acquisition of other reproductive tract conditions, such as
chlamydia, gonorrhea, candidiasis, and bacterial vaginosis (BV).7–18 Results from previous
studies on hormonal contraceptive use and Tv are conflicting.7,9,18–28 This could be due, in
part, to small sample sizes as well as differences in diagnostic and analytic methods used
among studies. The objective of this case–control study was to determine the relationship
between 2 types of hormonal contraceptive use, OC and DMPA, and prevalent Tv in women
attending sexually transmitted disease (STD) clinics in the Southeast United States.
MATERIALS AND METHODS
Study Design and Sample
We conducted a prospective, case–control study in 3 health department STD clinics located
in Durham and Raleigh, NC and Birmingham, AL, from November 2001 to July 2003. The
study was approved by the University of North Carolina at Chapel Hill and the University of
Alabama at Birmingham Biomedical Institutional Review Boards.
Female patients who were English-speaking, ≥18 years of age, and had no history of
previous prescreening or study enrollment were prescreened for the study, which involved
collection of specimens for wet mount microscopy and cultures for Tv detection. Women
were eligible for study enrollment if they had not used metronidazole for 4 weeks before,
and had a history of vaginal sex within 60 days of Tv culture collection. Women who had a
positive Tv wet mount microscopy test on prescreening received treatment and/or
counseling and were immediately recruited into the study. Women who had a negative Tv
wet mount test on prescreening but positive Tv culture results were contacted to return to the
clinic for treatment and/or counseling. These women were recruited into the study at their
return visit.
For every 3 female subjects with positive wet mount microscopy results for Tv who were
enrolled in the study, we recruited 1 prescreened woman with a negative wet mount
microscopy result. This case–control ratio was selected because this design was part of a
larger study that focused on enrolling women with Tv infection and their male sexual
partners.29 The cases and controls were not matched. Patients who were enrolled as controls
but were subsequently diagnosed with trichomoniasis by culture were reclassified as cases.
All enrolled participants provided written informed consent.
All study participants reported having had sex partners within 2 months before study
enrollment. Women were asked whether they used different types of contraception (condom,
spermicide, diaphragm, withdrawal, IUD, OC, DMPA, Nor-plant, had a hysterectomy or
tubal ligation, partner had a vasectomy, or “other” type of birth control) while having
vaginal sex with their sex partners within the past 2 months.
Clinical, Demographic, and Behavioral Data
A routine bimanual pelvic exam, vaginal specimen collection for wet mount microscopy,
and testing for other STIs were performed on all women presenting to the clinics for
evaluation. Routine testing for Chlamydia trachomatis was also performed, but was limited
to women aged ≤25 years in 1 clinic. HIV testing was offered to all prescreened women. In
addition to routine specimen collection, vaginal swabs for Tv culture, and Gram stains for
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BV diagnosis were collected from prescreened women. Upon enrollment, information about
demographics (including age, race/ethnicity, income, and educational level), sexual behavior
and douching practices was collected. Clinical information such as history of sexually
transmitted infections (STIs) was also obtained. Demographic, behavioral, and clinical data
were acquired from an in-person questionnaire administered by research personnel and from
medical records.
Laboratory Analyses
Wet mount microscopy for Tv was performed according to routine clinic procedures by
trained laboratory personnel at each site. Vaginal swabs were immediately placed in saline,
agitated and 1 drop of the solution was observed at 200× magnification. T. vaginalis culture
was performed using the InPouch culture system (Biomed, White City, OR). Culture swabs
were inoculated into culture pouches and were read daily up to 5 days after inoculation.
Testing for other STIs were also performed as previously described.29 Vaginal smear Gram
stains were performed and evaluated at University of Alabama at Birmingham using
Nugent’s criteria.30
Measures
Women with positive wet mount microscopy and/or Tv culture results (defined as the
presence of motile trichomonads) were categorized as having Tv. Women with negative wet
mount microscopy results and negative Tv culture results (defined as the absence of motile
trichomonads) were categorized as not being infected with Tv.
Hormonal contraception was defined to include oral contraception or birth control pills,
DMPA, and Norplant (levonorgestrel). Nonhormonal contraceptives included the
diaphragm, hysterectomy, partner vasectomy, withdrawal and spermicide. IUDs could be
categorized as either hormonal if they contained levonorgestrel or nonhormonal for the inert,
copper-based devices. However, because the frequency of observations were small for
Norplant (n = 7) and IUDs (n = 6), these contraceptives were not included in bivariable or
multivariable analyses.
A 3-level nominal exposure variable was created to assess hormonal contraceptive use
among the women with their most recent and/or most frequent sexual partners.29 The first
category consisted of women who used OC, the second category comprised women who
used DMPA, and the last category was made up of women who used nonhormonal
contraception with their most recent and/or most frequent sexual partners. Condom use was
not included in the exposure variable, because most women do not exclusively use condoms.
In this study, 45% of the women reported condom use, but only 9% of the women reported
exclusive condom use. However, since condom use can impact Tv transmission, whether the
participant used condoms with their sexual partner in the past 2 months was included in
bivariable analyses to assess potential confounding. In the analyses, each of the 2 exposed
groups (women who used OC and women who used DMPA) was compared with the
unexposed group, defined as women who used nonhormonal contraception.
Statistical Analyses
Data were double entered and analyzed using SAS software version 8 (SAS Corporation,
Cary, NC). Univariable analyses were conducted using frequency distributions of
categorical variables. Measures of central tendency and variability were assessed for
continuous variables. Bivariable analyses were performed to assess the association of
selected demographic and behavioral variables with trichomoniasis.
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Demographics (age, race/ethnicity, last year’s household income, highest educational level
attained), sexual behavior (past diagnosis with an STI other than Tv, coinfection with
gonorrhea, condom use in the past 2 months, number of different sex partners in the past
year, number of sexual partners in the past 2 months and number of times the woman had
sex in an average week), douching behavior (number of times in the past week, number of
times in an average week), and factors related to the vaginal microenvironment (concurrent
diagnosis with BV, level of vaginal lactobacilli) were assessed for inter-subgroup
differences and for confounding the associations between hormonal contraceptive use and
Tv.
We initially tested each covariable for intersubgroup differences and confounding by
creating a model with the exposure variable and 1 additional covariable, and comparing it
with a model containing only the exposure variable. Variables with substantive differences
in the exposure odds ratio (OR) and a likelihood ratio (LR) P value ≤0.10 were assessed in
multivariable analyses for intersubgroup differences. Variables that resulted in at least a
10% change in the OR were evaluated in multivariable models for confounding.
Adjusted prevalence OR and 95% CI for the association of interest were estimated using
unconditional multiple logistic regression. We used a backward elimination strategy.
Intersub-group differences were evaluated by comparing the LR for the models with and
without the interaction term and retaining variables with a LR P value ≤0.10. Confounding
was assessed by comparing the fully adjusted OR with the adjusted OR after removing
potentially confounding variables in order of the magnitude of the Wald χ2 test P value. We
repeated this process for covariables until the cumulative change in the OR for the exposure
was >10% compared with the fully adjusted OR.
Since Tv testing is limited in most clinics, we did not include history of previous Tv
infection in our analyses. However, we performed a sensitivity analysis to evaluate the
influence of prior Tv infection on the outcome by adjusting our final models for this variable
and assessing its influence on our results.
RESULTS
Study Population
Seven hundred ninety women were diagnosed with Tv by positive wet mount and/or culture
during prescreening, and 539 (68%) infected women participated in the study. Of these, 347
women reported nonhormonal contraceptive use, 50 reported using OC, and 30 women used
DMPA; these 427 women (79%) were included in the current analyses. Of the 203 women
negative for Tv recruited for the study, 177 (87%) agreed to participate. Of these, 144 (81%)
female controls were included in these analyses, of which 103 reported using non-hormonal
contraceptives, 31 used OC, and 10 used DMPA.
Among the 571 female participants with reported contraceptive use, the median age was
29.6 years (standard deviation, 9.0 years). Most women reported that they were black
(92.3%) in race/ethnicity, and 64.1% had a high school level of education or less. Last year’s
household income was reported as less than $12,000 for half of the women in the study. The
majority (77.2%) of women had previously been diagnosed with an STI other than Tv, and
66.0% had more than 1 sex partner in the past year. Most women (85.8%) did not use OC,
and 54.2% reported using condoms in the past 2 months.
Characteristics Associated With T. vaginalis
Older women (age ≥37 years) were more likely to have prevalent trichomoniasis compared
with younger women (Table 1). Black women were more likely to be infected with Tv
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compared with nonblack women, as were women with less (vs. more) education. Age, race,
and education remained significantly associated with trichomoniasis in the multivariable
analysis. Having had a past STI diagnosis, having had more than 1 (vs. 1) sexual partner in
the past year, BV status, and household income were not associated with having
trichomoniasis (Table 1).
Association Between Hormonal Contraceptive Use and T. vaginalis
In bivariable analyses, we observed an inverse association between OC use compared with
nonhormonal contraceptive use, and prevalent Tv (OR: 0.5; 95% CI: 0.3–0.8). After
adjusting for age, race/ethnicity, highest educational level attained, income, number of times
the woman douched in an average week, and condom use, this association no longer reached
statistical significance (OR: 0.9; 95% CI: 0.5–1.6).
There was no association between women who used DMPA and Tv in bivariable analysis
(OR: 1.0; 95% CI: 0.5–2.1). Adjusting for age, race/ethnicity, education, income, number of
times the woman douched in an average week, and condom use did not appreciably change
these results (OR: 1.4; 95% CI: 0.6–3.4) (Table 1).
Since routine Tv testing is limited in most STD clinics, we did not include prior Tv
diagnosis in our analyses but added it to our final model to assess its effect on our results.
Addition of prior Tv diagnosis did not substantively change our results (OC use: OR = 0.9,
95% CI = 0.5–1.7; DMPA use: OR = 1.4, 95% CI = 0.6–3.6).
DISCUSSION
Oral contraceptive use was marginally protective against Tv in our bivariable analysis. After
adjusting for covariables, however, this association was not statistically significant. Our
results are consistent with other investigators who reported no association between OC and
Tv,7,9,11,14,19,24,31,32 although direct comparison of results is challenging due to differences
in diagnostic and analytical methods. Most studies reporting a statistically significant
protective effect of OC on Tv used wet mount microscopy for diagnosis, bivariable analyses,
or failed to adjust for potentially important confounders such as age.2,15,20,22,23,25 To our
knowledge, this study is the first to use both Tv culture as the diagnostic reference standard
and to evaluate potentially important covariables in multivariable analyses.
Although we found no multivariable association between OC or DMPA and trichomoniasis,
sex hormones are known to affect STIs.6 Oral contraceptives are thought to influence
vaginal conditions and susceptibility to infection, including chlamydia, vaginal candidiasis,
and BV.7,9,13,14,22,25,33 The impact of OC use on Tv has not been determined although
several mechanisms for protection by OC against trichomoniasis have been hypothesized.
Oral contraceptives might alter host defenses to Tv because female sex hormones are known
to affect the reproductive tract immune response.34–37 For example, Tv infects vaginal
epithelium, which may be thicker in women using OC compared with women not on
hormonal contraception.38 The effects of OC hormones on the vaginal epithelium may
create an environment that is less hospitable for trichomonads. OC might also protect
against trichomoniasis by lowering vaginal lactoferrin concentrations. The mean vaginal
lactoferrin concentration in women on OC is significantly lower compared with women not
on OC, and is the primary source of iron for trichomonads.39 In vitro, Tv is positively
regulated by iron resulting in increased cytoadherance to vaginal epithelium, resistance to
complement lysis and synthesis of trichomonad adhesions.40–42 Therefore, Tv may be less
virulent in women taking OC.
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Estrogen may also directly affect Tv, which possesses estrogen receptors, and have been
demonstrated to slow Tv growth and decrease its attachment to mammalian cells when
added to cultures.43–45 However, in vivo studies suggest that estrogen may promote growth
of Tv. For example, the persistence of trichomoniasis was reported in a postmenopausal
woman (who was allergic to metronidazole) until she discontinued estrogen replacement
therapy.46 If estrogen promotes Tv growth in vivo, we might expect to observe a positive
association between OC and Tv. However, we found a possible inverse association between
OC and Tv in bivariable analysis that may be due to a net reduction of systemic and/or local
estrogen in women from OC. OC users are thought to have comparatively lower serum
levels of endogenous estrogen than women who do not use hormonal contraceptives.47 The
observed protective effect of OC could also result from the competitive binding of
exogenous estrogen to Tv estrogen receptors,22 impeding the stimulating effect of
endogenous estrogen. However, this association was no longer statistically significant in
multivariable analyses.
We found that DMPA use is not associated with having trichomoniasis. Few other studies
have evaluated this relationship, although authors of 2 studies conducted in Africa also
reported no association between DMPA and trichomoniasis compared with women using no
contraception.26,32 Both of these studies in Africa diagnosed Tv using wet mount
microscopy. Although the reason for a potential effect of DMPA use on Tv is not known,
some of the explanations discussed above, such as hormonal influence on the immune
system, may be biologically plausible.
The limitations of our study merit discussion. We did not collect information regarding the
duration of contraceptive use. Thus, it is possible that Tv infection occurred before
contraceptive use, resulting in exposure misclassification. We also lacked information on
hormonal contraceptive composition. Most OC include a combination of estrogen and
progesterone, though progesterone-only prescriptions exist. Furthermore, levels of
progesterone and estrogen may differ among combination OC. However, OC
misclassification should be nondifferential about Tv status and any resulting bias should be
toward the null.48 Trichomoniasis may also have been misclassified because of the
imperfect performance of culture detection. Although it is considered the diagnostic
reference standard, Tv culture is less sensitive than newer Tv nucleic acid amplification
based tests. Thus, some Tv diagnoses may have been missed. Likewise, this
misclassification should be nondifferential about contraceptive status, and the resulting bias
should lead to an underestimation of the true association.
Millions of women worldwide use contraception, and knowledge that contraceptives impact
STIs, may affect a woman’s contraceptive choice. We found no association between OC and
Tv nor between DMPA and Tv compared with women who use nonhormonal methods of
contraception. Given the popularity of hormonal contraception, the high burden of Tv in
certain populations and its health consequences, confirmation of these results from studies
which accurately and prospectively measure hormonal contraceptive use and assess Tv
infections using nucleic acid amplification based tests would be beneficial.
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